Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00796978
Recruitment Status : Completed
First Posted : November 24, 2008
Results First Posted : August 3, 2020
Last Update Posted : August 3, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Cynthia Owusu, MD, Case Comprehensive Cancer Center

Brief Summary:

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase II trial is studying the side effects of trastuzumab and to see how well it works in treating older women with early-stage breast cancer.


Condition or disease Intervention/treatment Phase
Breast Cancer Biological: trastuzumab Other: laboratory biomarker analysis Procedure: adjuvant therapy Procedure: quality-of-life assessment Phase 2

Detailed Description:

OBJECTIVES:

Primary

  • To evaluate the 3-year cumulative incidence of cardiac events in women 60 years and older with HER2-positive breast cancer who receive single agent trastuzumab (Herceptin®) in the adjuvant setting.

Secondary

  • To evaluate the 1-year cumulative incidence of asymptomatic cardiac left ventricular dysfunction in women 60 years and older with Her2-positive breast cancer who receive single agent trastuzumab in the adjuvant setting.
  • To evaluate long-term cardiac toxicity (5-year cumulative incidence of cardiac events) in women 60 years and older with Her2-positive breast cancer who receive single agent trastuzumab in the adjuvant setting.
  • To assess the relation between physiologic markers of chronic heart failure and trastuzumab-related cardiac dysfunction in women 60 years and older with Her2-positive breast cancer who receive single agent trastuzumab.
  • To assess the relation between pro-inflammatory cytokines and trastuzumab-related cardiac dysfunction in women 60 years and older with Her2-positive breast cancer.
  • To determine the effect of this drug on the health-related quality of life and functional, cognitive, and mental status of women 60 years and older with Her2-positive breast cancer.
  • To determine the 5-year disease-free survival and overall survival of women 60 years and older with Her2-positive breast cancer who receive single agent trastuzumab in the adjuvant setting.

OUTLINE: This is a multicenter study.

Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α). Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.

After completion of study therapy, patients are followed periodically for 4 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin®) in Older Women With Early-Stage and Locally Advanced Breast Cancer: A Phase II Trial
Actual Study Start Date : November 11, 2008
Actual Primary Completion Date : January 12, 2018
Actual Study Completion Date : January 12, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Trastuzumab

Arm Intervention/treatment
Experimental: trastuzumab Biological: trastuzumab
Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Other Name: Herceptin

Other: laboratory biomarker analysis
Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).

Procedure: adjuvant therapy
Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

Procedure: quality-of-life assessment
Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.




Primary Outcome Measures :
  1. Percent of Participants Experiencing Cardiac Events at 1 Year [ Time Frame: At 1 year ]
    Number of participants that experience cardiac events that include cardiac death due to congestive heart failure (CHF), Myocardial infarction (MI) or documented arrhythmia, death without definitive cause, or signs and symptoms of CHF as defined by New York Heart Association (NYHA) class III or IV symptoms.


Secondary Outcome Measures :
  1. Percent of Participants Experiencing Cardiac Events at 3 Years [ Time Frame: At 3 years ]
    Number of participants that experience cardiac events that include cardiac death due to congestive heart failure (CHF), Myocardial infarction (MI) or documented arrhythmia, death without definitive cause, or signs and symptoms of CHF as defined by New York Heart Association (NYHA) class III or IV symptoms.

  2. Percent of Participants Experiencing Cardiac Events at 5 Years [ Time Frame: At 5 years ]
    Number of participants that experience cardiac events that include cardiac death due to congestive heart failure (CHF), Myocardial infarction (MI) or documented arrhythmia, death without definitive cause, or signs and symptoms of CHF as defined by New York Heart Association (NYHA) class III or IV symptoms.

  3. Percent of Participants of Asymptomatic Left Ventricular (LV) Cardiac Dysfunction at 1 Year [ Time Frame: At 1 year ]
    One-year cumulative incidence of LV cardiac dysfunction as measured by percent of participants that had asymptomatic LV cardiac dysfunction with/without permanent discontinuation

  4. Percent of Participants With Asymptomatic LV Cardiac Dysfunction at Three Years [ Time Frame: At 3 years ]
    Three-year cumulative incidence of LV cardiac dysfunction as measured by percent of participants that had asymptomatic LV cardiac dysfunction with/without permanent discontinuation

  5. Percent of Participants With Asymptomatic LV Cardiac Dysfunction at Five Years [ Time Frame: At 5 years ]
    Five-year cumulative incidence as measured by percent of participants that had asymptomatic LV cardiac dysfunction with/without permanent discontinuation

  6. Percent of Participants With Disease-free Survival (DFS) [ Time Frame: At 1 year ]
    Percent of participants with DFS measured between the time from initiation of treatment to the date of first loco-regional or distant treatment failure, ignoring any intervening contralateral breast cancers or other second primary cancers. Deaths without evidence of recurrence will be treated censoring events.

  7. Percent of Participants With DFS [ Time Frame: At 2 years ]
    Percent of participants with DFS measured between the time from initiation of treatment to the date of first loco-regional or distant treatment failure, ignoring any intervening contralateral breast cancers or other second primary cancers. Deaths without evidence of recurrence will be treated censoring events.

  8. Percent of Participants With Disease-free Survival (DFS) [ Time Frame: At 3 years ]
    Percent of participants with DFS measured between the time from initiation of treatment to the date of first loco-regional or distant treatment failure, ignoring any intervening contralateral breast cancers or other second primary cancers. Deaths without evidence of recurrence will be treated censoring events.

  9. Percent of Participants With Disease-free Survival (DFS) [ Time Frame: At 5 years ]
    Percent of participants with DFS measured between the time from initiation of treatment to the date of first loco-regional or distant treatment failure, ignoring any intervening contralateral breast cancers or other second primary cancers. Deaths without evidence of recurrence will be treated censoring events.

  10. Overall Survival (OS) as Measured by Percent of Participants Alive at 1 Year [ Time Frame: Up to 1 years ]
    OS defined as percent of participants alive between time from initiation of treatment to the date of protocol-defined outcome from any cause and censored to the date of last follow-up for survivors.

  11. Overall Survival (OS) as Measured by Percent of Participants Alive at 2 Years [ Time Frame: Up to 2 years ]
    OS defined as percent of participants alive between time from initiation of treatment to the date of protocol-defined outcome from any cause and censored to the date of last follow-up for survivors.

  12. Overall Survival (OS) as Measured by Percent of Participants Alive at 3 Years [ Time Frame: Up to 3 years ]
    OS defined as percent of participants alive between time from initiation of treatment to the date of protocol-defined outcome from any cause and censored to the date of last follow-up for survivors.

  13. Overall Survival (OS) as Measured by Percent of Participants Alive at 5 Years [ Time Frame: Up to 5 years ]
    OS defined as percent of participants alive between time from initiation of treatment to the date of protocol-defined outcome from any cause and censored to the date of last follow-up for survivors.

  14. Mean Change in Quality of Life and Comprehensive Geriatric Assessment Scores From Baseline to Mid-treatment and Baseline to End of Treatment [ Time Frame: Baseline to week 26 and baseline to 52 weeks after being on study ]

Other Outcome Measures:
  1. Mean Change in Pro-inflammatory Cytokines From Baseline to Mid-treatment and Baseline to End of Treatment [ Time Frame: Every 6 weeks during treatment up to three years ]
  2. Mean Change in Plasma Cardiac Markers From Baseline to Mid-treatment and Baseline to End of Treatment [ Time Frame: Every 6 weeks during treatment up to three years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the breast
  • Immunohistochemical staining for Her2 protein of 3+ intensity or Her2 gene amplification of ≥ 2.0 by FISH testing.
  • Life expectancy > 6 months
  • ECOG performance status ≤ 2
  • Node positive disease irrespective of tumor size
  • Node negative disease:

    • TNM Stage (AJCC Cancer Staging Manual 6th edition) T1b-T4, N0-3, M0, irrespective of hormonal status
  • Baseline LVEF ≥ lower limit of normal for a particular institution
  • Complete surgical removal of invasive cancer by mastectomy or lumpectomy
  • Complete staging work-up with CT of chest, abdomen, and pelvis plus bone scan or alternatively with PET scan for stage II and higher disease, or as determined by symptoms for all other stages. Additional staging work-up as per symptoms.
  • Adequate bone marrow function as indicated by the following:

    • ANC >1000/µL
    • Platelets ≥100,000/µL
    • Hemoglobin >10 g/dL
  • Adequate liver function, as indicated by bilirubin ≤1.5 x upper limit of normal (ULN) Adequate renal function, as indicated by creatinine ≤1.5 x ULN
  • AST or ALT <2 x ULN unless related to primary disease.
  • Signed informed consent

Exclusion Criteria:

  • Enrollment after more than 120 days from the last day of mastectomy or lumpectomy
  • Patients able to tolerate and willing to receive chemotherapy
  • Prior chemotherapy for current malignancy
  • Prior herceptin therapy
  • Active cardiac disease

    • Myocardial infarction (asymptomatic changes on EKG suggestive of old MI is not an exclusion)
    • Angina pectoris requiring anti-anginal treatment
    • Documented congestive heart failure (CHF)
    • Current use of any therapy specifically for CHF
    • Cardiac arrhythmia requiring medication
    • Current uncontrolled hypertension (diastolic >100 mmHg or systolic > 200 mmHg)
    • Clinically significant valvular abnormality (associated with New York Heart Association (NYHA) class II, III, or IV symptoms)
    • Clinically significant pericardial effusion (associated with New York Heart Association (NYHA) class II, III, or IV symptoms)
  • Past cardiac disease

    • Prior myocardial infarction (asymptomatic changes on EKG suggestive of old MI is not an exclusion)
    • Prior history of CHF
    • History of cardiomyopathy
  • Other diseases and conditions

    • Evidence of metastatic breast cancer (clinical or radiological evidence)
    • Active infection
    • Concomitant malignancies or previous malignancies within the last 3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
    • Hypersensitivity to trastuzumab

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00796978


Locations
Layout table for location information
United States, Florida
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
United States, North Carolina
Wake Forrest
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Lake/University Seidman Cancer Center
Cleveland, Ohio, United States, 44060
Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
University Suburban Health Center
Cleveland, Ohio, United States, 44121
UHHS Chagrin Highlands Medical Center
Cleveland, Ohio, United States, 44122
Southwest General Health Center
Cleveland, Ohio, United States, 44130
UHHS Westlake Medical Center
Cleveland, Ohio, United States, 44145
UH-Monarch
Mayfield Heights, Ohio, United States, 44124
Sharon Health Center
Wadsworth, Ohio, United States, 44281
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Cynthia Owusu, MD
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Cynthia Owusu, MD, MSc University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
  Study Documents (Full-Text)

Documents provided by Cynthia Owusu, MD, Case Comprehensive Cancer Center:
Informed Consent Form  [PDF] November 17, 2019

Layout table for additonal information
Responsible Party: Cynthia Owusu, MD, Principal Investigator, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00796978    
Other Study ID Numbers: CASE10107
P30CA043703 ( U.S. NIH Grant/Contract )
CASE10107 ( Other Identifier: Case Comprehensive Cancer Center )
CASE-10107-CC443 ( Other Identifier: Cancer Center IRB )
First Posted: November 24, 2008    Key Record Dates
Results First Posted: August 3, 2020
Last Update Posted: August 3, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cynthia Owusu, MD, Case Comprehensive Cancer Center:
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
HER2-positive breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents